Recently, E-nitiate Biopharmaceuticals received the"Drug Clinical Trial Approval Notice"issued by CDE (Notice No. :2021LP01713), QY201 tablet was approved for clinical trial in the treatment of atopic dermatitis.
QY201 is a Jak1/Tyk2 dual target inhibitor developed independently by E-nitiate Biopharmaceuticals and the approved indication for phase I clinical trial is atopic dermatitis. Compared with other JAK inhibitors, QY201 showed higher JAK1/TYK2 inhibitory activity and selectivity. At the kinase level, the activity of JAK1 and TYK2 reached picomolar level and at the cellular level, the selectivity ratio for JAK2 over JAK1 is over 300. In both eczema and psoriasis animal models, QY201 showed superior activity, head to head, over some marketed drugs at the same dose.
Effects of targeting different JAKs[1]
Ding Shizhe, general manager of E-nitiate Biopharmaceuticals, said that with the improvement of living standards, people will pay more attention to improving the quality of life. However, at present, there are still huge unmet clinical needs for autoimmune skin diseases such as atopic dermatitis, psoriasis and alopecia areata. As a highly selective dual target inhibitor, QY201 has excellent efficacy, can effectively solve the side effects of non selective JAK inhibitors, and bring a better treatment experience to the majority of patients with skin diseases. It is an innovative drug worthy of expectation. QY201 project has the first approved IND since the establishment of the company. During this period, the internal departments of the company cooperated closely, linked efficiently, fully promoted the project and completed the approval in advance, which is a milestone of special significance for E-nitiate Biopharmaceuticals. At present, the research and development of Jak1/Tyk2 dual target inhibitors worldwide are in the clinical stage, and QY201 is expected to become the first listed Jak1/Tyk2 dual target inhibitor in China. Next, we will make every effort to carry out the clinical trial of QY201 project and strive to be approved for listing as soon as possible to benefit the majority of patients.
Betta fund reached strategic cooperation with E-nitiate Biopharmaceuticals
In recent years, while accelerating its own development, Betta pharmaceutical is also trying to help high-quality innovative projects realize industrialization. Betta fund and E-nitiate Biopharmaceuticals officially signed a strategic cooperation agreement on December 10, 2020 to implement non exclusive sharing and mutual cooperation in all aspects of resources related to innovative drugs. The two sides established a strategic cooperation relationship of sustainable development with an open mind in order to achieve win-win results. E-nitiate Biopharmaceuticals focuses on the research and development of new drugs for autoimmune diseases, with good development prospects and great development potential. In the future, Betta pharmaceutical will give full support to the development of E-nitiate Biopharmaceuticals and help E-nitiate Biopharmaceuticals develop into an excellent pharmaceutical innovation enterprise.
Reference：
[1]Daniella
M. Schwartz, Yuka Kanno, Alejandro Villarino, Michael Ward, Massimo
Gadina and John J. O'Shea. JAK inhibition as a therapeutic strategy for
immune and inflammatory diseases[J]. DRUG DISCOVERY ,16,847-862(2017).
About E-nitiate Biopharmaceuticals
E-nitiate Biopharmaceuticals (Hangzhou) Co.,Ltd, founded in 2020 by VivaVision Biotech and Betta fund, is a key introduction project of Linping National Development Zone. The company is committed to becoming a leader in the development of new drugs to solve the unmet medical needs for autoimmune diseases. QY201, QY101,QY211 and QY301, a class of innovative drugs with global patents, have entered or will enter the clinical stage. As Dr. Shen Wang, a senior medicinal chemist as the core, the team members used to work in many well-known pharmaceutical enterprises such as Amgen, Johnson & Johnson and Merck, companies with first-class drug R&D and industrialization abilities. The company is an innovative pharmaceutical company with great potential.
